| 1.41 -0.05 (-3.42%) | 12-12 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.87 |
1-year : | 2.09 |
| Resists | First : | 1.6 |
Second : | 1.78 |
| Pivot price | 1.42  |
|||
| Supports | First : | 1.29 | Second : | 1.08 |
| MAs | MA(5) : | 1.44 |
MA(20) : | 1.44 |
| MA(100) : | 1.55 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.6 |
D(3) : | 69.4 |
| RSI | RSI(14): 38.2 |
|||
| 52-week | High : | 3.9 | Low : | 1.16 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SBFM ] has closed above bottom band by 34.0%. Bollinger Bands are 63.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.46 - 1.47 | 1.47 - 1.48 |
| Low: | 1.36 - 1.38 | 1.38 - 1.38 |
| Close: | 1.4 - 1.41 | 1.41 - 1.42 |
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Tue, 28 Oct 2025
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM) - Yahoo Finance
Mon, 20 Oct 2025
Doxycycline 100 mg now nationwide — Sunshine Biopharma launches generic antibiotic in Canada - Stock Titan
Thu, 16 Oct 2025
Sunshine Biopharma’s Leap: Analyzing Key Developments - timothysykes.com
Thu, 16 Oct 2025
Sunshine Biopharma Stock Is Surging Thursday: Here's What's Happening - Benzinga
Thu, 16 Oct 2025
Sunshine Biopharma stock soars after launch of cholesterol drug Pravastatin - Investing.com
Thu, 16 Oct 2025
Sunshine Biopharma’s Meteoric Rise: Buy Opportunity? - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 7.5 (%) |
| Shares Short | 589 (K) |
| Shares Short P.Month | 365 (K) |
| EPS | 5.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.3 |
| Profit Margin | -16.1 % |
| Operating Margin | -5.7 % |
| Return on Assets (ttm) | -9.9 % |
| Return on Equity (ttm) | -24.4 % |
| Qtrly Rev. Growth | 11.6 % |
| Gross Profit (p.s.) | 2.5 |
| Sales Per Share | 7.6 |
| EBITDA (p.s.) | -0.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | 0.26 |
| PEG Ratio | 0 |
| Price to Book value | 0.26 |
| Price to Sales | 0.18 |
| Price to Cash Flow | -0.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|